# US 2008/0187547 A1 · Irta-5 antibodies and their uses

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0187547 A1
- Document ID: US20080187547A1
- Status: Published application
- Kind: A1
- Application number: 11/958,683
- Filed: 2007-12-18
- Published: 2008-08-07
- Earliest claimed: 2004-03-29
- Inventors: Robert Graziano; Josephine M. Cardarelli; Thomas D. Kempe; Beth Cutter; Mohan Srinivasan
- Web page: https://patentgrep.com/patent/US20080187547A1

## CPC

- C07K 16/3061: {Blood cells}
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 16/283: {against Fc-receptors, e.g. CD16, CD32, CD64 (CD23 C07K16/2851)}
- A61K 2039/505: {comprising antibodies}
- C07K 2317/21: from primates, e.g. man
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to IRTA-5 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting IRTA-5, as well as methods for treating various B cell malignancies, including non-Hodgkin's lymphoma.

## Claims

### Claim 1

An isolated monoclonal antibody, or an antigen-binding portion thereof, wherein the antibody:
(a) binds to human Immune Receptor Translocation Associated-5 (IRTA-5) amino acid sequence of SEQ ID NO: 37 with a KD of 5×10−8 M or less;
(b) selectively binds to human IRTA-5 having an amino acid sequence of SEQ ID NO: 37 by greater than about 10:1 as measured by immunoassay over human IRTA-1 having an amino acid sequence of SEQ ID NO: 38, IRTA-2 having an amino acid sequence of SEQ ID NO: 39, IRTA-3 having an amino acid sequence of SEQ ID NO: 40, and/or IRTA-4 having an amino acid sequence of SEQ ID NO: 41; and
(c) binds to human B lymphocytes and to B cell tumor lines but does not bind to CD3+ peripheral blood T cells, CD1A+ peripheral blood dendritic cells, CD14+ peripheral blood monocytes, or CD56+ peripheral blood natural killer cells.

### Claim 2 (depends on 1)

The antibody of claim 1, which is a human antibody.

### Claim 3 (depends on 2)

The antibody of claim 2, which is a full-length antibody of an IgG1 or IgG4 isotype.

### Claim 4 (depends on 2)

The antibody of claim 2, which is an antibody fragment or a single chain antibody.

### Claim 5 (depends on 2)

The antibody of claim 2, wherein said antibody binds to human IRTA-5 with a KD of 3×10−8 M or less.

### Claim 6 (depends on 2)

The antibody of claim 2, wherein said antibody binds to human IRTA-5 with a KD of 1×10−9 M or less.

### Claim 7 (depends on 2)

The antibody of claim 2, wherein said antibody binds to human IRTA-5 with a KD of 0.1×10−9 M or less.

### Claim 8 (depends on 2)

The antibody of claim 2, wherein said antibody binds to human IRTA-5 with a KD of 0.05×10−9 M or less.

### Claim 9 (depends on 2)

The antibody of claim 2, wherein said antibody binds to human IRTA-5 with a KD of between 1×10−9 and 1×10−11 M.

### Claim 10 (depends on 1)

The antibody of claim 1, wherein the B cell tumor lines are selected from the group consisting of Daudi, Ramos, and SU-DHL-4 cell lines.

### Claim 11

An isolated monoclonal antibody, or antigen binding portion thereof, wherein the antibody cross-competes for binding to IRTA-5 with a reference antibody, wherein the reference antibody:
(a) binds to human IRTA-5 amino acid sequence of SEQ ID NO: 37 with a KD of 5×10−8 M or less;
(b) selectively binds to human IRTA-5 having an amino acid sequence of SEQ ID NO: 37 by greater than about 10:1 as measured by immunoassay over human IRTA-1 having an amino acid sequence of SEQ ID NO: 38, IRTA-2 having an amino acid sequence of SEQ ID NO: 39, IRTA-3 having an amino acid sequence of SEQ ID NO: 40, and/or IRTA-4 having an amino acid sequence of SEQ ID NO:41; and
(c) binds to human B lymphocytes and to B cell tumor lines but does not bind to CD3+ peripheral blood T cells, CD1A+ peripheral blood dendritic cells, CD14+ peripheral blood monocytes, or CD56+ peripheral blood natural killer cells.

### Claim 12 (depends on 11)

The antibody of claim 11, wherein the reference antibody comprises:
(a) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 19; and
(b) a light chain variable region comprising the amino acid sequence of SEQ ID NO: 22.

### Claim 13 (depends on 11)

The antibody of claim 11, wherein the reference antibody comprises:
(a) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 20; and
(b) a light chain variable region comprising the amino acid sequence of SEQ ID NO: 23.

### Claim 14 (depends on 11)

The antibody of claim 11, wherein the reference antibody comprises:
(a) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 21; and
(b) a light chain variable region comprising the amino acid sequence of SEQ ID NO: 24.

### Claim 15

An isolated monoclonal antibody, or an antigen-binding portion thereof, comprising a heavy chain variable region that is the product of a human VH 3-33 gene, a human VH DP44 gene, a human VH 3-23 gene or a human VH 3-7 gene, wherein the antibody specifically binds IRTA-5 amino acid sequence of SEQ ID NO: 37.

### Claim 16

An isolated monoclonal antibody, or an antigen-binding portion thereof, comprising a light chain variable region that is the product of a human VK L6 gene, wherein the antibody specifically binds IRTA-5 amino acid sequence of SEQ ID NO: 37.

### Claim 17 (depends on 16)

The isolated monoclonal antibody, or an antigen-binding portion thereof, of claim 16 further comprising:
a heavy chain variable region of a human VH 3-33, VH DP44, VH 3-23, or VH 3-7 gene.

### Claim 18 (depends on 17)

The antibody of claim 17, which comprises a heavy chain variable region of a human VH 3-33 gene and a light chain variable region of a human VK L6 gene.

### Claim 19 (depends on 17)

The antibody of claim 17, which comprises a heavy chain variable region of a human VH DP44 gene and a light chain variable region of a human VK L6 gene.

### Claim 20 (depends on 17)

The antibody of claim 17, which comprises a heavy chain variable region of a human VH 3-23 gene and a light chain variable region of a human VK L6 gene.

### Claim 21 (depends on 17)

The antibody of claim 17, which comprises a heavy chain variable region of a human VH 3-7 gene and a light chain variable region of a human VK L6 gene.

### Claim 22 (depends on 17)

The antibody of claim 17, wherein the antibody selectively binds to human IRTA-5 having an amino acid sequence of SEQ ID NO: 37 by greater than about 10:1 as measured by immunoassay over human IRTA-1 having an amino acid sequence of SEQ ID NO: 38, IRTA-2 having an amino acid sequence of SEQ ID NO: 39, IRTA-3 having an amino acid sequence of SEQ ID NO: 40, and/or IRTA-4 having an amino acid sequence of SEQ ID NO: 41.

### Claim 23 (depends on 1)

The antibody of claim 1, which comprises:
(a) a heavy chain variable region CDR1 comprising SEQ ID NO: 1;
(b) a heavy chain variable region CDR2 comprising SEQ ID NO: 4;
(c) a heavy chain variable region CDR3 comprising SEQ ID NO: 7;
(d) a light chain variable region CDR1 comprising SEQ ID NO: 10;
(e) a light chain variable region CDR2 comprising SEQ ID NO: 13; and
(f) a light chain variable region CDR3 comprising SEQ ID NO: 16.

### Claim 24 (depends on 1)

The antibody of claim 1, which comprises:
(a) a heavy chain variable region CDR1 comprising SEQ ID NO: 2;
(b) a heavy chain variable region CDR2 comprising SEQ ID NO: 5;
(c) a heavy chain variable region CDR3 comprising SEQ ID NO: 8:
(d) a light chain variable region CDR1 comprising SEQ ID NO: 11;
(e) a light chain variable region CDR2 comprising SEQ ID NO: 14;
(f) a light chain variable region CDR3 comprising SEQ ID NO: 17.

### Claim 25 (depends on 1)

The antibody of claim 1, which comprises:
(a) a heavy chain variable region CDR1 comprising SEQ ID NO: 3;
(b) a heavy chain variable region CDR2 comprising SEQ ID NO: 6;
(c) a heavy chain variable region CDR3 comprising SEQ ID NO: 9;
(d) a light chain variable region CDR1 comprising SEQ ID NO: 12;
(e) a light chain variable region CDR2 comprising SEQ ID NO: 15; and
(f) a light chain variable region CDR3 comprising SEQ ID NO: 18.

### Claim 26 (depends on 1)

The antibody of claim 1, which comprises:
(a) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 19; and
(b) a light chain variable region comprising the amino acid sequence of SEQ ID NO: 22.

### Claim 27 (depends on 1)

The antibody of claim 1, which comprises:
(a) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 20; and
(b) a light chain variable region comprising the amino acid sequence of SEQ ID NO: 23.

### Claim 28 (depends on 1)

The antibody of claim 1, which comprises:
(a) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 21 or 36; and
(b) a light chain variable region comprising the amino acid sequence of SEQ ID NO: 24.

### Claim 29 (depends on 1)

A composition comprising the antibody, or antigen-binding portion thereof, of claim 1, and a pharmaceutically acceptable carrier.

### Claim 30 (depends on 1)

The antibody of claim 1, wherein the antibody selectively binds to human IRTA-5 having an amino acid sequence of SEQ ID NO: 37 by greater than about 100:1 over human IRTA-1 having an amino acid sequence of SEQ ID NO: 38, IRTA-2 having an amino acid sequence of SEQ ID NO: 39, IRTA-3 having an amino acid sequence of SEQ ID NO: 40, and/or IRTA-4 having an amino acid sequence of SEQ ID NO: 41.

### Claim 31 (depends on 11)

The antibody of claim 11, wherein the antibody selectively binds to human IRTA-5 having an amino acid sequence of SEQ ID NO: 37 by greater than about 100:1 over human IRTA-1 having an amino acid sequence of SEQ ID NO: 38, IRTA-2 having an amino acid sequence of SEQ ID NO: 39, IRTA-3 having an amino acid sequence of SEQ ID NO: 40, and/or IRTA-4 having an amino acid sequence of SEQ ID NO: 41.

### Claim 32 (depends on 22)

The antibody of claim 22, wherein the antibody selectively binds to human IRTA-5 having an amino acid sequence of SEQ ID NO: 37 by greater than about 100:1 over human IRTA-1 having an amino acid sequence of SEQ ID NO: 38, IRTA-2 having an amino acid sequence of SEQ ID NO: 39, IRTA-3 having an amino acid sequence of SEQ ID NO: 40, and/or IRTA-4 having an amino acid sequence of SEQ ID NO: 41.

### Claim 33

An isolated monoclonal antibody, or an antigen-binding portion thereof, wherein the antibody:
(a) binds to human Immune Receptor Translocation Associated-5 (IRTA-5) having an amino acid sequence of SEQ ID NO: 37 with a KD of 5×10−8 M or less; and
(b) selectively binds to human IRTA-5 having an amino acid sequence of SEQ ID NO: 37 by greater than about 10:1 as measured by immunoassay over human IRTA-1 having an amino acid sequence of SEQ ID NO: 38, IRTA-2 having an amino acid sequence of SEQ ID NO: 39, IRTA-3 having an amino acid sequence of SEQ ID NO: 40, and/or IRTA-4 having an amino acid sequence of SEQ ID NO:41.

### Claim 34 (depends on 33)

The antibody of claim 33, wherein the antibody selectively binds to human IRTA-5 having an amino acid sequence of SEQ ID NO: 37 by greater than about 100:1 over human IRTA-1 having an amino acid sequence of SEQ ID NO: 38, IRTA-2 having an amino acid sequence of SEQ ID NO: 39, IRTA-3 having an amino acid sequence of SEQ ID NO: 40, and/or IRTA-4 having an amino acid sequence of SEQ ID NO: 41.
